| Literature DB >> 25506275 |
Bernice L Hausman1, Mecal Ghebremichael2, Philip Hayek1, Erin Mack3.
Abstract
In this article, we analyze newspaper articles and advertisements mentioning vaccination from 1915 to 1922 and refer to historical studies of vaccination practices and attitudes in the early 20th century in order to assess historical continuities and discontinuities in vaccination concern. In the Progressive Era period, there were a number of themes or features that resonated with contemporary issues and circumstances: 1) fears of vaccine contamination; 2) distrust of medical professionals; 3) resistance to compulsory vaccination; and 4) the local nature of vaccination concern. Such observations help scholars and practitioners understand vaccine skepticism as longstanding, locally situated, and linked to the sociocultural contexts in which vaccination occurs and is mandated for particular segments of the population. A rhetorical approach offers a way to understand how discourses are engaged and mobilized for particular purposes in historical contexts. Historically situating vaccine hesitancy and addressing its articulation with a particular rhetorical ecology offers scholars and practitioners a robust understanding of vaccination concerns that can, and should, influence current approaches to vaccination skepticism.Keywords: immunization; rhetorical ecology; smallpox; vaccination; vaccine
Mesh:
Year: 2014 PMID: 25506275 PMCID: PMC4257028
Source DB: PubMed Journal: Yale J Biol Med ISSN: 0044-0086
Comparison of U.S. national vaccination rates, 1995 and 2013.
|
|
|
|
|
|
|
| DTaP | Diphtheria, Tetanus, and Pertussis | 3+ | 94.1 | 94.7 (DTP) | Acellular pertussis vaccine introduced in 1996 |
| IPV | Poliovirus | 3+ | 92.7 | 87.9 (both IPV and OPV) | Inactivated poliovirus vaccine. Until 2000, both IPV and OPV (oral poliovirus vaccine) were used in the U.S. |
| MMR | Measles, Mumps, and Rubella | 1+ | 91.9 | 87.8 | Booster at 4-6 years |
| HepA | Hepatitis A | 1+ | 83.1 | n/a | 1+ dose; 2 doses by 2 years for all children recommended since 2005 |
| HepB | Hepatitis B | 3+ | 90.8 | 68 | Introduced as routine vaccine in 1990s |
| Hib | Bacterial meningitis caused by Haemophilus influenza type b | 3+ | 92.8 | 91.7 | |
| RV | Rotavirus | 2+ or 3+ | 72.6 | n/a | Rotarix® (RV1; 2+ doses; approved for use in 2008) and Rota Teq® (RV5; 3+ doses; approved for use in 2006) |
| VAR | Varicella or Chicken Pox | 1+ | 91.2 | 25.9 (1997) | 1st available 1995 |
| PCV | Pneumococcal disease | 3+ | 92.4 | 73.2 (2004) | Pneumococcal conjugate vaccine, started 2000 |
| Series 4:3:1:3:3:1** | 77.7 | 72.5 | DTaP:IPV:MMR:Hib:HepB:VAR | ||
| Series 4:3:1:3:3:1:4** | 72.6 | 30.8 (2003) | DTaP:IPV:MMR:Hib:HepB:VAR:PCV |
Source: National Immunization Survey (NIS) - Children (19-35 months). Available from http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/index.html.
*Influenza vaccine is not included in this table. While it is a recommended vaccine for children, it is a yearly vaccine and does not appear to be tracked in the National Immunization Survey.
**Rates for the vaccine series are lower than rates for the individual vaccines because some children do not complete the whole series but receive most of the vaccines. These series are comprised of vaccines recommended by the CDC for all children in the U.S. by 18 months: in the mid-1990s (4:3:1:3:3:1) and in the early 2000s (4:3:1:3:3:1:4).